Dr. Reddy's Secures Brazil Approval for Generic Semaglutide Injection
RDY sits 30% above its 52-week low of $11.36.
Summary
Brazil's ANVISA approved Dr. Reddy's generic semaglutide injection for type 2 diabetes, opening a market the company estimates at about USD 244.6 million. Dr. Reddy's plans to launch there with partner Aché; no launch date or financial terms were given.
Key Events · Product Development and Regulatory · RDY
-
ANVISA Approves Generic Semaglutide
Brazil's regulator granted marketing authorization for generic semaglutide injection for adults with insufficiently controlled type 2 diabetes, as an adjunct to diet and exercise.
-
Market Sized at ~$244.6M
Dr. Reddy's cites IQVIA (MAT September 2026) putting the Brazilian semaglutide diabetes market at approximately USD 244.6 million, with 16.6 million adults aged 20-79 living with diabetes in Brazil.
-
Two Pen Presentations, Weekly Dosing
The product will be sold as pre-filled multi-dose injectable pens in 2 mg/1.5 mL and 4 mg/3 mL strengths for once-weekly dosing.
-
Launch Planned With Aché
CEO of Global Generics MV Ramana said Dr. Reddy's plans to launch semaglutide in Brazil with partner Aché; no launch date or pricing was disclosed.
Analysis · RDY · Life Sciences
ANVISA has cleared Dr. Reddy's generic semaglutide in Brazil, a diabetes market the company sizes at roughly USD 244.6 million — meaningful, though not transformative for a company of this scale. The approval extends the semaglutide franchise into a second major emerging market and comes with a named launch partner, Aché, sharing commercialization risk. Strategic weight lies in the GLP-1 build-out: Dr. Reddy's is positioning itself as a low-cost semaglutide supplier across markets, and each approval strengthens that case. Against a backdrop of USFDA observations at three Indian plants since August and a 36% year-over-year drop in Q2 FY2026 profit on weaker North America generics, emerging-market GLP-1 revenue offers a useful offset. No financial terms, launch date, or pricing were disclosed.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RDY was trading at $14.75 on NYSE in the Life Sciences sector, with a market capitalization of approximately $12.1B. The 52-week trading range was $11.36 to $15.67. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.